Friday, March 11, 2011

Pharma profits - what will happen when the patents expire

The Boston Globe has an interesting piece about how the expiration of patents will be a huge blow to the gravy train to many pharma companies.  Click here for the article.  Here is an excerpt: "At the end of November, Pfizer stands to lose a $10-billion-a-year revenue stream when the patent on its blockbuster drug Lipitor expires and cheaper generics begin to cut into the company’s huge sales."

In our off-label qui tam cases, we have seen that the expiration of a patent is often a motivating factor for pharma companies to promote their products for off-label indications.

Hat tip: PharmaGossip.

No comments:

Post a Comment